JPMorgan Chase & Co. Reaffirms Neutral Rating for TransMedics Group (NASDAQ:TMDX)

JPMorgan Chase & Co. reaffirmed their neutral rating on shares of TransMedics Group (NASDAQ:TMDX) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. JPMorgan Chase & Co. currently has a $75.00 price objective on the stock, down from their prior price objective of $116.00.

A number of other equities analysts have also commented on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Piper Sandler lowered their price target on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Canaccord Genuity Group reduced their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Oppenheimer reiterated an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a research report on Tuesday, December 3rd. Finally, Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Trading Down 0.6 %

Shares of NASDAQ TMDX opened at $60.53 on Tuesday. The firm has a 50 day moving average price of $89.89 and a two-hundred day moving average price of $129.32. The stock has a market cap of $2.03 billion, a P/E ratio of 64.39 and a beta of 2.06. TransMedics Group has a 52-week low of $60.17 and a 52-week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business’s revenue for the quarter was up 63.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.12) earnings per share. As a group, equities analysts forecast that TransMedics Group will post 1 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total value of $1,144,623.75. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,180,642.53. This trade represents a 12.27 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now directly owns 732 shares in the company, valued at approximately $61,158.60. This trade represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 19,417 shares of company stock valued at $2,240,738. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Large investors have recently modified their holdings of the company. Driehaus Capital Management LLC increased its stake in TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after purchasing an additional 202,867 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after buying an additional 146,115 shares during the last quarter. Hood River Capital Management LLC acquired a new position in shares of TransMedics Group during the second quarter valued at about $18,854,000. Canada Pension Plan Investment Board bought a new stake in shares of TransMedics Group during the second quarter worth about $16,086,000. Finally, F M Investments LLC acquired a new stake in shares of TransMedics Group in the 2nd quarter worth about $10,957,000. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.